OncoResponse Announces Poster Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022)
SEATTLE, Washington - October 5, 2022 – OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced that it will present two abstracts at the upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting being held November 8-12, 2022, in Boston.
Details are as follows:
Title: Interrogating Elite Responder humoral responses to identify novel targets and therapeutic antibodies for the treatment of cancer
Abstract Number: 39
Details: Thursday, November 10, 2022, 9 a.m. to 9 p.m. EST
Title: Preclinical characterization of OR502, an anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression
Abstract Number: 498
Details: Friday, November 11, 9 a.m. to 8:30 p.m. EST
OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of Elite Responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies. OR2805 is a fully human antibody discovered using B cells derived from an Elite Responder to checkpoint inhibitor (CPI) therapy. Additional pipeline candidates that modulate suppressive macrophage activity are under development. OncoResponse is a privately held company backed by investment from MD Anderson Cancer Center, Rivervest Venture Partners, Qatar Investment Authority, Redmile Group, Magnetar Group, Yonjin Venture, InterVest, Bering Capital, ARCH Venture Partners, Helsinn Investment Fund, Canaan Partners, GreatPoint Ventures, Takeda Ventures, Buchang Pharma, Alexandria Real Estate Equities and William Marsh Rice University. For more information, please visit www.oncoresponse.com and follow us on LinkedIn and Twitter.